Treatment dose and the elimination rates of electrolytes, vitamins, and trace elements during continuous veno-venous hemodialysis (CVVHD)
During continuous renal replacement therapy, achievement of recommended treatment dose is important. However, relevant substrate loss may occur and recommended nutrition during critical illness could not be sufficient for higher dialysis doses. We investigated the correlation of dialysis dose and substrate loss for a broad range of dialysis doses.
Forty critically ill patients with acute kidney injury undergoing citrate CVVHD were included in this prospective study. Three different corresponding blood flow (BF) and dialysate flow (DF) rates were applied (BF/DF: 100 ml/min, 2000 ml/h; 80 ml/min, 1500 ml/h; 120 ml/min, 2500 ml/h). Delivered effluent flow rate (DEFR) was calculated and correlated with losses of vitamins, electrolytes, and trace elements during recommended nutritional supplementation.
For folic acid, vitamin B12, zinc, inorganic phosphate, and magnesium, no correlation of losses and DEFR was detected. For ionized calcium, a correlation was observed and additional substitution was required.
Clinically relevant loss of folic acid, vitamin B12, zinc, inorganic phosphate, and magnesium was not observed for differently used dialysis doses of CVVHD, and the loss was covered sufficiently by daily recommended nutritional supplementation. Increased loss of ionized calcium for higher dialysis doses occurred during citrate CVVHD. Therefore, a strict protocol must maintain calcium homeostasis to avoid calcium depletion.
KeywordsAcute kidney injury Continuous renal replacement therapy Citrate anticoagulation Critical illness Trace elements
The authors would like to acknowledge the support of Gerald Steinbach from the Department of Clinical Chemistry at the University Hospital Ulm.
Compliance with ethical standards
Conflict of interest
Karl Träger received honoraria for lectures from Fresenius Medical Care.
- 3.Morgera S, Schneider M, Slowinski T, Vargas-Hein O, Zuckermann-Becker H, Peters H, Kindgen-Milles D, Neumayer H-H (2009) A safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acid-base status. Crit Care Med 37(6):2018–2024. https://doi.org/10.1097/CCM.0b013e3181a00a92 CrossRefPubMedGoogle Scholar
- 8.Datzmann T, Träger K, Reinelt H, von Freyberg P (2017) Elimination rates of electrolytes, vitamins, and trace elements during continuous renal replacement therapy (CRRT) with citrate CVVHD—influence of filter lifetime. Blood Purif 44(3):210–216. https://doi.org/10.1159/000477454 CrossRefPubMedGoogle Scholar
- 10.Section 2: AKI Definition (2012) Kidney Int Suppl 2(1):19–36. https://doi.org/10.1038/kisup.2011.32
- 20.Section 5: Dialysis Interventions for Treatment of AKI (2012). Kidney Int Suppl (2011) 2(1):89–115. https://doi.org/10.1038/kisup.2011.35